Aline de Cristo Soares Alves
◽
Franciele Aline Bruinsmann
◽
Silvia Stanisçuaski Guterres
◽
Adriana Raffin Pohlmann
Bevacizumab (BCZ) is a recombinant humanized monoclonal antibody against the vascular endothelial growth factor, which is involved in the angiogenesis process. Pathologic angiogenesis is observed in several diseases including ophthalmic disorders and cancer. The multiple administrations of BCZ can cause adverse effects. In this way, the development of controlled release systems for BCZ delivery can promote the modification of drug pharmacokinetics and, consequently, decrease the dose, toxicity, and cost due to improved efficacy. This review highlights BCZ formulated in organic nanoparticles providing an overview of the physicochemical characterization and in vitro and in vivo biological evaluations. Moreover, the main advantages and limitations of the different approaches are discussed. Despite difficulties in working with antibodies, those nanocarriers provided advantages in BCZ protection against degradation guaranteeing bioactivity maintenance.
Photoinduced Architectural Transformation of Noncovalent Fluorescent Photochromic Organic Nanoparticles as Evidenced by Amplified Fluorescence Photoswitching
